Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2026-07-06 16:31:00 ET · period of report 2026-07-01 · accession 0001797917-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-06 16:31 | 2026-07-01 | KROS | Prener Anne | Dir | A - Grant | $0.00 | +13.8K | 13.8K | New | $0 |
| D | 2026-07-06 16:31 | 2026-07-01 | KROS | Prener Anne | Dir | A - Grant | $0.00 | +14.9K | 14.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-01 | A | A | 13,786 | $0.00 | 13,786 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs shall vest over a three-year period in twelve equal quarterly installments with the first such vesting to occur on August 15, 2026, subject to the Reporting Person's continuous service through each such vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2026-07-01 | A | A | 14,870 | $0.00 | 14,870 | D | $10.88 · — to 2036-06-30 | 14,870 Common Stock | (F2) The shares subject to the option shall vest over a three-year period in equal quarterly installments with the first such vesting to occur on October 1, 2026, subject to the Reporting Person's continuous service through each such vesting date. |